Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
Brazil
Study Type
Interventional
Intervention
EMS Acarbose
Bayer Acarbose
Sponsored by
About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Patients must be able to understand the study procedures agree to participate and give written consent.
- Diagnosed with type 2 diabetes mellitus (t2dm)b
- Female patients of childbearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) which agree to use a medically accepted contraceptive regimen for the duration of the study.
Exclusion Criteria:
- Pregnancy or risk of pregnancy.
- Lactation
- Any pathology or past medical condition that can interfere with this protocol
- Other conditions deemed reasonable by the medical investigator as to the disqualification of the individual from study participation.
- Known hypersensitivity / intolerance to acarbose or any of its excipients
Sites / Locations
- Marcio Antonio Pereira Clinica
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
EMS Acarbose
Bayer Acarbose
Arm Description
Outcomes
Primary Outcome Measures
Glycosylated hemoglobin (HbA1c)
Secondary Outcome Measures
Decrease in mean Fasting Plasma Glucose (FPG)
Safety will be evaluated by the Adverse events occurence
Adverse events will be collected and followed in order to evaluate safety and tolerability
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01316861
Brief Title
Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus
Official Title
A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
September 2013
Overall Recruitment Status
Completed
Study Start Date
September 2012 (undefined)
Primary Completion Date
March 2013 (Actual)
Study Completion Date
May 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
EMS
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The Purpose of This Study is to Evaluate the Efficacy and Safety of Acarbose in Type 2 Diabetic Patients Using Two Different Formulations of Acarbose 50mg.
Detailed Description
Study Design:
Multicenter
Phase III
Randomized
Double Blind
Prospective and Comparative
Experiment duration: 105 days
5 visits
Efficacy
Adverse event
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
79 (Actual)
8. Arms, Groups, and Interventions
Arm Title
EMS Acarbose
Arm Type
Experimental
Arm Title
Bayer Acarbose
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
EMS Acarbose
Intervention Description
EMS Acarbose 50 mg 3 times a day
Intervention Type
Drug
Intervention Name(s)
Bayer Acarbose
Intervention Description
Bayer Acarbose 50 mg 3 times a day
Primary Outcome Measure Information:
Title
Glycosylated hemoglobin (HbA1c)
Time Frame
Change from baseline to day 98
Secondary Outcome Measure Information:
Title
Decrease in mean Fasting Plasma Glucose (FPG)
Time Frame
Change from baseline to day 14, 28, 42, 70 and 98
Title
Safety will be evaluated by the Adverse events occurence
Description
Adverse events will be collected and followed in order to evaluate safety and tolerability
Time Frame
Day 105
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients must be able to understand the study procedures agree to participate and give written consent.
Diagnosed with type 2 diabetes mellitus (t2dm)b
Female patients of childbearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) which agree to use a medically accepted contraceptive regimen for the duration of the study.
Exclusion Criteria:
Pregnancy or risk of pregnancy.
Lactation
Any pathology or past medical condition that can interfere with this protocol
Other conditions deemed reasonable by the medical investigator as to the disqualification of the individual from study participation.
Known hypersensitivity / intolerance to acarbose or any of its excipients
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Felipe Pinho, MD
Organizational Affiliation
EMS S/A
Official's Role
Study Director
Facility Information:
Facility Name
Marcio Antonio Pereira Clinica
City
Sao Jose Dos Campos
State/Province
SP
ZIP/Postal Code
12.245-000
Country
Brazil
12. IPD Sharing Statement
Learn more about this trial
Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs